These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35112095)

  • 21. Atherosclerotic Coronary Plaque Regression and Risk of Adverse Cardiovascular Events: A Systematic Review and Updated Meta-Regression Analysis.
    Iatan I; Guan M; Humphries KH; Yeoh E; Mancini GBJ
    JAMA Cardiol; 2023 Oct; 8(10):937-945. PubMed ID: 37647074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-HDL Cholesterol and Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events.
    Puri R; Nissen SE; Shao M; Elshazly MB; Kataoka Y; Kapadia SR; Tuzcu EM; Nicholls SJ
    Arterioscler Thromb Vasc Biol; 2016 Nov; 36(11):2220-2228. PubMed ID: 27515380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN.
    Stegman B; Puri R; Cho L; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nissen SE; Nicholls SJ
    Diabetes Care; 2014 Nov; 37(11):3114-20. PubMed ID: 25190674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
    Puri R; Nissen SE; Somaratne R; Cho L; Kastelein JJ; Ballantyne CM; Koenig W; Anderson TJ; Yang J; Kassahun H; Wasserman SM; Scott R; Borgman M; Nicholls SJ
    Am Heart J; 2016 Jun; 176():83-92. PubMed ID: 27264224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of baseline lipoprotein and C-reactive protein levels on coronary atheroma regression following high-intensity statin therapy.
    Puri R; Nissen SE; Shao M; Uno K; Kataoka Y; Kapadia SR; Tuzcu EM; Nicholls SJ
    Am J Cardiol; 2014 Nov; 114(10):1465-72. PubMed ID: 25282317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
    Tsujita K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Yamanaga K; Komura N; Sakamoto K; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
    J Am Coll Cardiol; 2015 Aug; 66(5):495-507. PubMed ID: 26227186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implications of Total to High-Density Lipoprotein Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events.
    Elshazly MB; Nicholls SJ; Nissen SE; St John J; Martin SS; Jones SR; Quispe R; Stegman B; Kapadia SR; Tuzcu EM; Puri R
    Am J Cardiol; 2016 Sep; 118(5):647-55. PubMed ID: 27392507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between changes in coronary atherosclerotic plaque burden measured by intravascular ultrasound and cardiovascular disease outcomes: a systematic literature review.
    Forbes C; Quek RG; Deshpande S; Worthy G; Ross J; Kleijnen J; Gandra SR; Kassahun H; Wong ND; Nicholls SJ
    Curr Med Res Opin; 2016 Jun; 32(6):1143-50. PubMed ID: 26949994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
    Nicholls SJ; Tuzcu EM; Sipahi I; Grasso AW; Schoenhagen P; Hu T; Wolski K; Crowe T; Desai MY; Hazen SL; Kapadia SR; Nissen SE
    JAMA; 2007 Feb; 297(5):499-508. PubMed ID: 17284700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial.
    Zanchin C; Koskinas KC; Ueki Y; Losdat S; Häner JD; Bär S; Otsuka T; Inderkum A; Jensen MRJ; Lonborg J; Fahrni G; Ondracek AS; Daemen J; van Geuns RJ; Iglesias JF; Matter CM; Spirk D; Juni P; Mach F; Heg D; Engstrom T; Lang I; Windecker S; Räber L
    Am Heart J; 2021 Aug; 238():33-44. PubMed ID: 33951415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
    Nissen SE
    Am J Cardiol; 2005 Sep; 96(5A):61F-68F. PubMed ID: 16126025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: insights from intravascular ultrasound.
    Kataoka Y; Shao M; Wolski K; Uno K; Puri R; Murat Tuzcu E; Hazen SL; Nissen SE; Nicholls SJ
    Atherosclerosis; 2014 Feb; 232(2):377-83. PubMed ID: 24468151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral Calcium Supplements Associate With Serial Coronary Calcification: Insights From Intravascular Ultrasound.
    Bazarbashi N; Kapadia SR; Nicholls SJ; Carlo J; Gad MM; Kaur M; Karrthik A; Sammour YM; Diab M; Ahuja KR; Tuzcu EM; Nissen SE; Puri R
    JACC Cardiovasc Imaging; 2021 Jan; 14(1):259-268. PubMed ID: 32828785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease.
    Elshazly MB; Mani P; Nissen S; Brennan DM; Clark D; Martin S; Jones SR; Quispe R; Donnellan E; Nicholls SJ; Puri R
    Eur J Prev Cardiol; 2020 Jul; 27(10):1091-1100. PubMed ID: 31744333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
    Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJ; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Scott R; Ungi I; Podolec J; Ophuis AO; Cornel JH; Borgman M; Brennan DM; Nissen SE
    JAMA; 2016 Dec; 316(22):2373-2384. PubMed ID: 27846344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndromes and hypercholesterolemia not adequately controlled with statins: ODYSSEY J-IVUS rationale and design.
    Ako J; Hibi K; Kozuma K; Miyauchi K; Morino Y; Shinke T; Tsujita K; Uno K; Kawabata Y; Hiro T
    J Cardiol; 2018 Jun; 71(6):583-589. PubMed ID: 29606415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial.
    Nicholls SJ; Andrews J; Kastelein JJP; Merkely B; Nissen SE; Ray KK; Schwartz GG; Worthley SG; Keyserling C; Dasseux JL; Griffith L; Kim SW; Janssan A; Di Giovanni G; Pisaniello AD; Scherer DJ; Psaltis PJ; Butters J
    JAMA Cardiol; 2018 Sep; 3(9):815-822. PubMed ID: 30046828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy of glycemic control with continuous glucose monitoring on atheroma progression: rationale and design of the Observation of Coronary Atheroma Progression under Continuous Glucose Monitoring Guidance in Patients with Type 2 Diabetes Mellitus (OPTIMAL).
    Kataoka Y; Hosoda K; Makino H; Matsubara M; Matsuo M; Ohata Y; Koezuka R; Tamanaha T; Tomita T; Honda-Kohmo K; Noguchi M; Son C; Nishimura K; Asaumi Y; Miyamoto Y; Noguchi T; Yasuda S
    Cardiovasc Diagn Ther; 2019 Oct; 9(5):431-438. PubMed ID: 31737515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden.
    Kataoka Y; Andrews J; Duong M; Nguyen T; Schwarz N; Fendler J; Puri R; Butters J; Keyserling C; Paolini JF; Dasseux JL; Nicholls SJ
    Cardiovasc Diagn Ther; 2017 Jun; 7(3):252-263. PubMed ID: 28567351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Visit-to-Visit Blood Pressure Variability, Coronary Atheroma Progression, and Clinical Outcomes.
    Clark D; Nicholls SJ; St John J; Elshazly MB; Ahmed HM; Khraishah H; Nissen SE; Puri R
    JAMA Cardiol; 2019 May; 4(5):437-443. PubMed ID: 30969323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.